Skip to main content
2024 Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Qi Liu, MStat, FCP, PhD

Associate Director for Innovation & Partnership
US Food & Drug Administration

Qi Liu, Ph.D., M.Stat., FCP is the Associate Director for Innovation & Partnership in the Office of Clinical Pharmacology (OCP)/ Office of Translational Sciences, CDER, FDA. She leads OCP’s innovative initiatives through strategic partnership. She has helped developing OCP’s portfolio on artificial intelligence/ machine learning, real world evidence and digital health technologies, collaborating with internal and external experts. She helped establishing the OCP Innovative Data Analytics Program and AI/ML review team, and currently serves as the lead. She had the experience leading OCP’s Physiological Based Pharmacokinetic Modeling and Simulation Oversight Board and co-leading Biologics Oversight Board. She is also on the executive board of CDER’s Quantitative Medicine Center of Excellence. She was a co-lead initiating the Real-Time Oncology Review and Assessment Aid Pilot Programs. During her career at the FDA, she also contributed to over 200 NDA/sNDA reviews, 20 BLA/sBLA reviews, and numerous IND reviews to support drug development. She worked on working groups for FDA guidance documents and Manual of Policies & Procedures development. She is an Associate Editor of Clinical Translational Science and on the editorial board of five scientific journals. Before joining FDA, Dr. Liu was a senior pharmacokineticist at Merck & Co. Inc. She obtained her Ph.D. degree in Pharmaceutics and a concurrent Master's degree in Statistics from the University of Florida in 2004. In addition, she has a Master's degree in Pharmaceutics and a Bachelors’ degree in Clinical Pharmacy from West China University of Medical Sciences.

Disclosure information not submitted.

Presentation(s):